awmsg logo



certolizumab pegol (Cimzia®)


Reference No. 1211

Publication date:
31/10/2014


Appraisal information

certolizumab pegol (Cimzia®) 200 mg solution for injection


Company: UCB Pharma Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 3114
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Certolizumab pegol (Cimzia®) is recommended as an option for use within NHS Wales for the treatment of adult patients with severe active axial spondyloarthritis, comprising: adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs); and adults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download